Cigarette Smoking Clinical Trial
— CameraCue3Official title:
Effects of Smoking Environments on Brain Reactivity
Verified date | December 2020 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to evaluate correlations between brain reactivity (as assessed via functional magnetic resonance imaging (fMRI) following 24-h abstinence) and the amount of smoking in a specific location. The investigators will use ecological momentary assessment (EMA) to ask smokers to rate their exposure to, and smoking in, specific personal smoking environment cues (PSEs) over the course of 2 weeks before quitting smoking and 2 weeks after quitting smoking. The investigators propose to identify 48 regular cigarette smokers who will complete 8 visits (1 screening visit, 1 training visit, 1 camera turn-in visit, 1 fMRI session and 4 post-quit medication check sessions). Multiple methods will be used to test hypotheses about brain functioning during cue-reactivity (CR). The investigators will examine correlation between brain responses to smoking environments (minus non-smoking environments) and smoking cessation outcomes (i.e. days to lapse, days to relapse). Our EMA+Global Positioning System (GPS) analysis will primarily focus on locations where smokers smoke before and after quitting smoking. The investigators will evaluate whether EMA-assessed smoking intensity values are correlated with brain responses to these personal smoking environments.
Status | Completed |
Enrollment | 88 |
Est. completion date | December 23, 2019 |
Est. primary completion date | October 16, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. generally healthy [(i.e. ambulatory, not currently sick)] 2. between the ages of 18 and 65 3. smoking of at least 5 cig/day of a brand delivering = 0.5 mg nicotine (FTC method) for > 1 year 4. an expired carbon monoxide (CO) concentration of at least 10 ppm (to confirm inhalation) or urinary cotinine >1000 ng/mL (NicAlert = 6). 5. interest in quitting smoking within the timeframe of the experiment. 6. ability to identify 4 personal smoking and 4 personal non-smoking places. 7. right handed as measured by a three-item scale used in our laboratory 8. own a smartphone Exclusion Criteria: 1. immediate or no desire to quit smoking; 2. inability to attend all required experimental sessions; 3. use of other tobacco products or e-cigarettes more than 9 days in the past 30 days; 4. current alcohol or drug abuse; 5. positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and Phencyclidine(PCP) 1. marijuana will be tested for but will not be exclusionary; 2. participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded; 3. participants failing the toxicology screen will be allowed to re-screen once; 6. current use of nicotine replacement therapy or other smoking cessation treatment; 7. screening systolic BP greater than 140 (participants failing for blood pressure will be allowed to rescreen once) 8. screening diastolic BP greater than 90 (participants failing for blood pressure will be allowed to rescreen once) 9. screening heart rate greater than 100 (participants failing for heart rate will be allowed to rescreen once) 10. presence of conditions contraindicated for nicotine replacement therapy (e.g., skin allergies) 11. report of significant health problems including but not restricted to (e.g. chronic hypertension, emphysema, seizure disorder, history of significant heart problems, heart disease, heart attack in the past 90 days, irregular heartbeat) 12. medical condition that may contraindicate participation in the opinion of the investigator and study physician. 13. current major psychiatric disease such as schizophrenia or schizoaffective disorder 14. currently pregnant, breast feeding or likely to become pregnant; 15. a quit attempt resulting in greater than 3 days of abstinence in the past 30 days 16. presence of conditions that would make MRI unsafe (e.g., pacemaker) |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Signal Change in Functional Magnetic Resonance Imaging (fMRI) Contrast of Parameter Estimate (COPE) Between Personal Environment Pictures Relative to Non-Personal Environment Pictures | Using fMRI the investigators examined brain function during cue-reactivity. During the scan, participants viewed pictures of personal and non-personal environments.
Contrast of parameter estimate (COPE) values for the difference between personal smoking environment pictures and non-personal smoking environment pictures were extracted from anatomically defined brain regions using FSL's featquery for analysis. |
4 weeks | |
Secondary | Post-Quit Craving as Measured by (Ecological Momentary Assessment) EMA Questionnaire | EMA will be used to evaluate craving daily for 2 weeks after quitting. Subjects will rate their craving on a single item (How strong is your current urge to smoke?) using a scale from 1 "very slightly or not at all" to 5 "extremely". | 2 weeks after quitting smoking | |
Secondary | Number of Participants Experiencing Relapse | Relapse defined as 7 consecutive days smoking at least 1 cigarette per day. Individuals lost to contact are presumed to have relapsed following their last visit. | Weeks 1, 3, 6, and 10 weeks after quitting. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Active, not recruiting |
NCT02643914 -
Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
|
N/A | |
Recruiting |
NCT02422914 -
Benefits of Tobacco Free Cigarette
|
N/A | |
Active, not recruiting |
NCT02629679 -
Sports, Education and Consumption of Substances in Adolescents
|
N/A | |
Completed |
NCT02385227 -
Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes
|
N/A | |
Completed |
NCT02218281 -
Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation
|
N/A | |
Completed |
NCT01199380 -
Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
|
Phase 2 | |
Completed |
NCT01692353 -
Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers
|
N/A | |
Completed |
NCT01081119 -
Brief Voluntary Alcohol and Drug Intervention for Middle School Youth
|
Phase 2 | |
Completed |
NCT00802919 -
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
|
Phase 4 | |
Completed |
NCT00756704 -
The Effectiveness of Smoking Cessation Guidelines in the Emergency Department
|
N/A | |
Completed |
NCT00682474 -
School Nurse-Delivered Smoking Cessation Intervention
|
Phase 2/Phase 3 | |
Completed |
NCT05520775 -
Semaglutide for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT03743532 -
E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services
|
N/A | |
Terminated |
NCT03840694 -
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior
|
N/A | |
Completed |
NCT06032793 -
Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.
|
N/A | |
Terminated |
NCT03326128 -
High Dose Bupropion for Smoking Cessation - Pilot Study
|
Phase 2 | |
Recruiting |
NCT03218670 -
Your Health in On Click
|
N/A | |
Completed |
NCT02538042 -
Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)
|
N/A |